S2157|T39799|TargetMol

价格	询价
包装	1removed

最小起订量	1removed
发货地	上海
更新日期	2026-05-08

QQ交谈微信洽谈

产品详情

中文名称:S2157	英文名称:S2157
CAS:2262488-39-9	品牌: TargetMol
产地: 美国	保存条件: Powder: -20°C for 3 years \| In solvent: -80°C for 1 year
产品类别: 抑制剂
货号: T39799

Product Introduction

Bioactivity

名称	S2157
描述	S2157, a potent N-alkylated tranylcypromine (TCP) derivative lysine-specific demethylase 1 (LSD1) inhibitor, enhances H3K9 methylation and concurrently reduces H3K27 acetylation at super-enhancer sites. This compound triggers apoptosis in TCP-resistant T-cell acute lymphoblastic leukemia (T-ALL) cells by inhibiting NOTCH3 and TAL1 gene expression. Moreover, S2157 is capable of crossing the blood-brain barrier, effectively eliminating central nervous system (CNS) leukemia in mice models implanted with T-ALL cells.
体外活性	S2157 is particularly effective for T-ALL cell lines with the IC 50 values between 1.1 μM for human T-ALL cell lines CEM and 6.8 μM for MOLT4[1]. S2157 (4-20 μM; 72 hours) modestly inhibits mitogen-activated normal T-lymphocytes[1]. S2157 (4-8 μM; 24 hours) induces apoptosis and down-regulates the expression of NOTCH3 and TAL1 proteins in T-cell acute lymphoblastic leukemia (T-ALL) cells[1]. Cell Viability Assay[1]Cell Line: Normal T-lymphocytes Concentration: 4, 8, 12, 16, 20 μM Incubation Time: For 72 hours Result: Modestly inhibited mitogen-activated normal T-lymphocytes. Apoptosis Analysis[1]Cell Line: T-cell acute lymphoblastic leukemia (T-ALL) cells Concentration: 4, 6, 8 μM Incubation Time: For 24 hours Result: Induced apoptosis, as evidenced by increased annexin-V reactivity on flow cytometry in T-ALL cells in a dose- and time-dependent manner without affecting cell cycle distribution. Western Blot Analysis[1]Cell Line: T-ALL cells Concentration: 4, 6, 8 μM Incubation Time: For 24 hours Result: Down-regulated the expression of NOTCH3 and TAL1 proteins in T-ALL cells.
体内活性	S2157 (50 mg/kg; IP; 3 times a week; for 28 days) causes the size of subcutaneous tumors reduced to less than 20% of that in the untreated control[1]. S2157 (50 mg/kg; IP) has a T 1/2 of 0.88 hours, a C max of 4.33 μM and an AUC of 5.75 μM?h[1]. S2157 (30 mg/kg or 50 mg/kg; twice a week for 3 weeks) almost completely suppressed the growth of MOLT4 cells in most but not all NOD/SCID mice with MOLT4 cells. S2157 eradicates CNS leukemia in murine xenotransplanted models[1]. Animal Model: Nonobese diabetic/severe combined immunodeficiency (NOD/SCID) mice with MOLT4 cells[1]Dosage: 50 mg/kg Administration: IP; 3 times a week; for 28 days Result: The size of subcutaneous tumors reduced to less than 20% of that in the untreated control. Animal Model: 8-week-old ICR mice[1]Dosage: 50 mg/kg (Pharmacokinetic Analysis) Administration: IP Result: Had a T 1/2 of 0.88 hours, a C max of 4.33 μM and an AUC of 5.75 μM?h.
存储条件	Powder: -20°C for 3 years \| In solvent: -80°C for 1 year
关键字	S-2157 \| S 2157
相关产品	Formamide \| Urea \| Sodium Molybdate \| Dimethyl phthalate \| Aceglutamide \| Alginic acid \| Cysteamine hydrochloride \| Metronidazole \| Sildenafil citrate \| Citric Acid Triammonium \| Stavudine \| Tamoxifen

关键字： S2157|TargetMol

公司简介

TargetMol Chemicals Inc. 总部位于马萨诸塞州波士顿，致力于为全球生化领域科学家的研究提供专业的产品和服务。TargetMol?品牌的客户群分布于40多个国家和地区，已发展成为全球知名的化合物库和小分子化合物研究供应商。 TargetMol?可提供160多种满足不同需求的化合物库，以及多种类型的生化试剂产品，包括12000多种抑制剂、16000多种天然产物和各类多肽、抗体、生命科学试剂盒等，此外，我们还建设有CADD（计算机辅助药物设计）研究中心、药理实验室、药化合成平台三大技术中心，全方位满足客户的定制需求。凭借我们优质的产品和服务、快速高效的全球供应链和专业的技术支持，我们将有效帮助您缩短研发周期，取得更成功的结果。

成立日期	2013-04-18 （14年）	注册资本	589.8595万人民币
员工人数	100-500人	年营业额	￥ 1亿以上
主营行业	中间体,天然产物,生物化工,化学试剂,生物技术服务	经营模式	贸易,工厂,试剂,定制,服务

TargetMol中国（陶术生物）

VIP 3年

公司成立：14年
注册资本：589.8595万人民币
企业类型：有限责任公司(自然人投资或控股)
主营产品：抑制剂&激动剂，天然产物，重组蛋白，化合物库，技术服务
公司地址：上海市静安区江场三路238号8楼

进入店铺

询盘

店内推荐

化合物 PD-135666|T28340|TargetMol

￥15300

化合物 BETi-211|T26780|TargetMol

询价

Triperiden|T38952|TargetMol

￥162

内容声明:
以上所展示的信息由商家自行提供，内容的真实性、准确性和合法性由发布商家负责。商家发布价格指该商品的参考价格，并非原价，该价格可能随着市场变化，或是由于您购买数量不同或所选规格不同而发生变化。最终成交价格，请咨询商家，以实际成交价格为准。请意识到互联网交易中的风险是客观存在的